{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:13:19Z","timestamp":1792800799437,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IBA"},{"name":"Beaumont Health Herb and Betty Fisher Research Seed Grant","id":[{"id":"https:\/\/ror.org\/05g2hd893","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To explore the dosimetric improvement, delivery efficiency, and plan robustness for bilateral head and neck cancer (HNC) treatment utilizing a novel proton therapy technique \u2013 the spot-scanning proton arc (SPArc) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated fourteen bilateral HNC patients retrospectively. Both SPArc and 3-field Intensity Modulated Proton Therapy (IMPT) plans were generated for each patient using the same robust optimization parameters. The prescription doses were 70Gy (relative biological effectiveness (RBE) for CTV_high and 60Gy[RBE] for CTV_low. Clinically significant dosimetric parameters were extracted and compared. Root-mean-square deviation dose (RMSDs) Volume Histogram(RVH) was used to evaluate the plan robustness. Total treatment delivery time was estimated based on the machine parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The SPArc plan was able to provide equivalent or better robust target coverage while showed significant dosimetric improvements over IMPT in most of the organs at risk (OARs). More specifically, it reduced the mean dose of the ipsilateral parotid, contralateral parotid, and oral cavity by 25.8%(\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), 20.8%(\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and 20.3%(p\u2009=\u20090.001) respectively compared to IMPT. This technique reduced D1 (the maximum dose covering 1% volume of a structure) of cord and brain stem by 20.8% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009) and 10.7% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048), respectively. SPArc also reduced the average integral dose by 17.2%(p\u2009=\u20090.001) and external V3Gy (the volume received 3Gy[RBE]) by 8.3%(\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008) as well. RVH analysis showed that the SPArc plans reduced the dose uncertainties in most OARs compared to IMPT, such as cord: 1.1\u2009\u00b1\u20090.4Gy[RBE] vs 0.7\u2009\u00b1\u20090.3Gy[RBE](p\u2009=\u20090.001), brain stem: 0.9\u2009\u00b1\u20090.7Gy[RBE] vs 0.7\u2009\u00b1\u20090.7Gy[RBE](\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), contralateral parotid: 2.5\u2009\u00b1\u20090.5Gy[RBE] vs 2.2\u2009\u00b1\u20090.6Gy[RBE](\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022) and ipsilateral parotid: 3.1\u2009\u00b1\u20090.7Gy[RBE] vs 2.8\u2009\u00b1\u20090.6Gy[RBE](\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) respectively. The average total estimated treatment delivery time were 283.4\u2009\u00b1\u200956.2\u2009s, 469.2\u2009\u00b1\u200962.0\u2009s and 1294.9\u2009\u00b1\u2009106.7\u2009s based on energy-layer-switching-time (ELST) of 0.1\u2009s, 1\u2009s, and 5\u2009s respectively for SPArc plans, compared to the respective values of 328.0\u2009\u00b1\u200947.6\u2009s(\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), 434.1\u2009\u00b1\u200952.0\u2009s(p\u2009=\u20090.002), and 901.7\u2009\u00b1\u200974.8\u2009s(\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) for 3-field IMPT plans. The potential clinical benefit of utilizing SPArc will lead to a decrease in the mean probability of salivary flow dysfunction by 31.3%(p\u2009=\u20090.001) compared with IMPT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SPArc could significantly spare OARs while providing a similar or better robust target coverage compared with IMPT in the treatment of bilateral HNC. In the modern proton system with ELST less than 0.5\u2009s, SPArc could potentially be implemented in the routine clinic with a practical, achievable treatment delivery efficiency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-020-1476-9","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T02:03:08Z","timestamp":1580349788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study"],"prefix":"10.1186","volume":"15","author":[{"given":"Gang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Kabolizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"1476_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0360-3016(00)01441-3","volume":"49","author":"KSC Chao","year":"2001","unstructured":"Chao KSC, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol. 2001;49:907\u201316.","journal-title":"Int J Radiat Oncol."},{"key":"1476_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ijrobp.2009.09.067","volume":"78","author":"P Dirix","year":"2010","unstructured":"Dirix P, Vanstraelen B, Jorissen M, Vander Poorten V, Nuyts S. Intensity-modulated radiotherapy for Sinonasal Cancer: improved outcome compared to conventional radiotherapy. Int J Radiat Oncol. 2010;78:998\u20131004.","journal-title":"Int J Radiat Oncol."},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.ijrobp.2009.04.011","volume":"76","author":"A Eisbruch","year":"2010","unstructured":"Eisbruch A, Harris J, Garden AS, Chao CKS, Straube W, Harari PM, et al. Multi-institutional trial of accelerated Hypofractionated intensity-modulated radiation therapy for early-stage Oropharyngeal Cancer (RTOG 00-22). Int J Radiat Oncol. 2010;76:1333\u20138.","journal-title":"Int J Radiat Oncol."},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0167-8140(01)00403-0","volume":"61","author":"L Cozzi","year":"2001","unstructured":"Cozzi L, Fogliata A, Lomax A, Bolsi A. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol. 2001;61:287\u201397.","journal-title":"Radiother Oncol"},{"key":"1476_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.radonc.2006.07.025","volume":"80","author":"M Steneker","year":"2006","unstructured":"Steneker M, Lomax A, Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. Radiother Oncol. 2006;80:263\u20137.","journal-title":"Radiother Oncol"},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.ijrobp.2010.05.012","volume":"79","author":"TA van de Water","year":"2011","unstructured":"van de Water TA, Lomax AJ, Bijl HP, de Jong ME, Schilstra C, Hug EB, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in Oropharyngeal Cancer. Int J Radiat Oncol. 2011;79:1216\u201324.","journal-title":"Int J Radiat Oncol."},{"key":"1476_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1078\/0939-3889-00217","volume":"14","author":"AJ Lomax","year":"2004","unstructured":"Lomax AJ, Pedroni E, Rutz HP, Goitein G. The clinical potential of intensity modulated proton therapy. Z F\u00fcr Med Phys. 2004;14:147\u201352.","journal-title":"Z F\u00fcr Med Phys"},{"key":"1476_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1088\/0031-9155\/53\/4\/015","volume":"53","author":"AJ Lomax","year":"2008","unstructured":"Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions. Phys Med Biol. 2008;53:1043\u201356.","journal-title":"Phys Med Biol"},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1088\/0031-9155\/53\/4\/014","volume":"53","author":"AJ Lomax","year":"2008","unstructured":"Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol. 2008;53:1027\u201342.","journal-title":"Phys Med Biol"},{"key":"1476_CR10","doi-asserted-by":"crossref","unstructured":"Cubillos-Mes\u00edas M, Baumann M, Troost EGC, Lohaus F, L\u00f6ck S, Richter C, et al. Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. Radiat Oncol [Internet]. 2017 [cited 2018 Jun 26];12. Available from: https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-017-0931-8","DOI":"10.1186\/s13014-017-0931-8"},{"key":"1476_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/0284186X.2017.1358463","volume":"57","author":"X Ding","year":"2018","unstructured":"Ding X, Li X, Qin A, Zhou J, Yan D, Stevens C, et al. Have we reached proton beam therapy dosimetric limitations? \u2013 a novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2018;57:435\u20137.","journal-title":"Acta Oncol"},{"key":"1476_CR12","doi-asserted-by":"crossref","unstructured":"Ding X, Li X, Qin A, Zhou J, Yan D, Chen P, et al. Redefine the role of range shifter in treating bilateral head and neck cancer in the era of Intensity Modulated Proton Therapy. J Appl Clin Med Phys [Internet]. 2018 [cited 2018 Jul 23]; Available from: http:\/\/doi.wiley.com\/10.1002\/acm2.12416","DOI":"10.1002\/acm2.12416"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.14338\/IJPT-15-00026.1","volume":"2","author":"A Moignier","year":"2016","unstructured":"Moignier A, Gelover E, Wang D, Smith B, Flynn R, Kirk M, et al. Improving head and neck Cancer treatments using dynamic collimation in spot scanning proton therapy. Int J Part Ther. 2016;2:544\u201354.","journal-title":"Int J Part Ther"},{"key":"1476_CR14","doi-asserted-by":"publisher","first-page":"121705","DOI":"10.1118\/1.4901260","volume":"41","author":"D Wang","year":"2014","unstructured":"Wang D, Dirksen B, Hyer DE, Buatti JM, Sheybani A, Dinges E, et al. Impact of spot size on plan quality of spot scanning proton radiosurgery for peripheral brain lesions: spot scanning proton radiosurgery. Med Phys. 2014;41:121705.","journal-title":"Med Phys"},{"key":"1476_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ijrobp.2008.02.059","volume":"72","author":"T Dijkema","year":"2008","unstructured":"Dijkema T, Terhaard CHJ, Roesink JM, Braam PM, van Gils CH, Moerland MA, et al. Large cohort dose\u2013volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy. Int J Radiat Oncol. 2008;72:1101\u20139.","journal-title":"Int J Radiat Oncol."},{"key":"1476_CR16","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1118\/1.4954790","volume":"43","author":"H Paganetti","year":"2016","unstructured":"Paganetti H, Yu CX, Orton CG. Photon radiotherapy has reached its limit in terms of catching up dosimetrically with proton therapy: point\/counterpoint. Med Phys. 2016;43:4470\u20132.","journal-title":"Med Phys"},{"key":"1476_CR17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.ijrobp.2016.08.049","volume":"96","author":"X Ding","year":"2016","unstructured":"Ding X, Li X, Zhang JM, Kabolizadeh P, Stevens C, Yan D. Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy. Int J Radiat Oncol Biol Phys. 2016;96:1107\u201316.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1476_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2019.04.032","volume":"137","author":"X Li","year":"2019","unstructured":"Li X, Liu G, Janssens G, De Wilde O, Bossier V, Lerot X, et al. The first prototype of spot-scanning proton arc treatment delivery. Radiother Oncol. 2019;137:130\u20136.","journal-title":"Radiother Oncol"},{"key":"1476_CR19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.ijrobp.2011.09.015","volume":"83","author":"EM Quan","year":"2012","unstructured":"Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate Cancer treatment. Int J Radiat Oncol. 2012;83:1169\u201378.","journal-title":"Int J Radiat Oncol"},{"key":"1476_CR20","doi-asserted-by":"crossref","unstructured":"Li X, Kabolizadeh P, Yan D, Qin A, Zhou J, Hong Y, et al. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy. Radiat Oncol [Internet]. 2018 [cited 2018 Jun 17];13. Available from: https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-018-0981-6","DOI":"10.1186\/s13014-018-0981-6"},{"key":"1476_CR21","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.ijrobp.2005.11.005","volume":"64","author":"H Aoyama","year":"2006","unstructured":"Aoyama H, Westerly DC, Mackie TR, Olivera GH, Bentzen SM, Patel RR, et al. Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol. 2006;64:962\u20137.","journal-title":"Int J Radiat Oncol."},{"key":"1476_CR22","doi-asserted-by":"publisher","DOI":"10.1118\/1.4801899","volume":"40","author":"W Liu","year":"2013","unstructured":"Liu W, Frank SJ, Li X, Li Y, Park PC, Dong L, et al. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers: robust optimization for IMPT for H&N cancer. Med Phys. 2013;40:051711.","journal-title":"Med Phys"},{"key":"1476_CR23","first-page":"1","volume":"0","author":"X Ding","year":"2019","unstructured":"Ding X, Zhou J, Li X, Blas K, Liu G, Wang Y, et al. Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. Acta Oncol. 2019;0:1\u20138.","journal-title":"Acta Oncol"},{"key":"1476_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1088\/0031-9155\/53\/3\/014","volume":"53","author":"VA Semenenko","year":"2008","unstructured":"Semenenko VA, Li XA. Lyman\u2013Kutcher\u2013Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol. 2008;53:737\u201355.","journal-title":"Phys Med Biol"},{"key":"1476_CR25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/0360-3016(89)90972-3","volume":"16","author":"GJ Kutcher","year":"1989","unstructured":"Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method Gerald. Int J Radiat Oncol. 1989;16:1623\u201330.","journal-title":"Int J Radiat Oncol."},{"issue":"2","key":"1476_CR26","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2307\/3576626","volume":"104","author":"John T. Lyman","year":"1985","unstructured":"Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res. 1985;104:13\u20139.","journal-title":"Radiation Research"},{"key":"1476_CR27","doi-asserted-by":"publisher","first-page":"e0152477","DOI":"10.1371\/journal.pone.0152477","volume":"11","author":"LV van Dijk","year":"2016","unstructured":"van Dijk LV, Steenbakkers RJHM, ten Haken B, van der Laan HP, van \u2018t Veld AA, Langendijk JA, et al. Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients. PLOS ONE. 2016;11:e0152477.","journal-title":"PLOS ONE"},{"key":"1476_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(09)70231-1","volume":"11","author":"P Dirix","year":"2010","unstructured":"Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol. 2010;11:85\u201391.","journal-title":"Lancet Oncol"},{"key":"1476_CR29","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/JCO.2007.14.6647","volume":"26","author":"JA Langendijk","year":"2008","unstructured":"Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck Cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770\u20136.","journal-title":"J Clin Oncol"},{"key":"1476_CR30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1088\/0031-9155\/53\/6\/013","volume":"53","author":"D Pflugfelder","year":"2008","unstructured":"Pflugfelder D, Wilkens JJ, Oelfke U. Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy. Phys Med Biol. 2008;53:1689\u2013700.","journal-title":"Phys Med Biol"},{"key":"1476_CR31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.ijrobp.2013.09.014","volume":"87","author":"AC Kraan","year":"2013","unstructured":"Kraan AC, van de Water S, Teguh DN, Al-Mamgani A, Madden T, Kooy HM, et al. Dose uncertainties in IMPT for Oropharyngeal Cancer in the presence of anatomical, range, and setup errors. Int J Radiat Oncol. 2013;87:888\u201396.","journal-title":"Int J Radiat Oncol."},{"key":"1476_CR32","doi-asserted-by":"publisher","first-page":"e1263","DOI":"10.1259\/bjr\/27428078","volume":"85","author":"AH Aitkenhead","year":"2012","unstructured":"Aitkenhead AH, Bugg D, Rowbottom CG, Smith E, Mackay RI. Modelling the throughput capacity of a single-accelerator multitreatment room proton therapy Centre. Br J Radiol. 2012;85:e1263\u201372.","journal-title":"Br J Radiol"},{"key":"1476_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2010-0171","volume":"16","author":"TA van de Water","year":"2011","unstructured":"van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck Cancer with respect to Normal tissue sparing: a systematic review of literature. Oncologist. 2011;16:366\u201377.","journal-title":"Oncologist"},{"key":"1476_CR34","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1088\/0031-9155\/60\/6\/2167","volume":"60","author":"K Kainz","year":"2015","unstructured":"Kainz K, Firat S, Wilson JF, Schultz C, Siker M, Wang A, et al. Comparing the quality of passively-scattered proton and photon tomotherapy plans for brain and head and neck disease sites. Phys Med Biol. 2015;60:2167\u201377.","journal-title":"Phys Med Biol"},{"key":"1476_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1120\/jacmp.v17i2.5798","volume":"17","author":"W Matysiak","year":"2016","unstructured":"Matysiak W, Yeung D, Slopsema R, Li Z. Evaluation of the range shifter model for proton pencil-beam scanning for the eclipse v.11 treatment planning system. J Appl Clin Med Phys. 2016;17:391\u2013404.","journal-title":"J Appl Clin Med Phys"},{"key":"1476_CR36","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1118\/1.4908208","volume":"42","author":"J Shen","year":"2015","unstructured":"Shen J, Liu W, Anand A, Stoker JB, Ding X, Fatyga M, et al. Impact of range shifter material on proton pencil beam spot characteristics. Med Phys. 2015;42:1335\u201340.","journal-title":"Med Phys"},{"key":"1476_CR37","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1088\/0031-9155\/53\/6\/003","volume":"53","author":"B Schaffner","year":"2008","unstructured":"Schaffner B. Proton dose calculation based on in-air fluence measurements. Phys Med Biol. 2008;53:1545\u201362.","journal-title":"Phys Med Biol"},{"key":"1476_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ejmp.2018.12.014","volume":"57","author":"F Fracchiolla","year":"2019","unstructured":"Fracchiolla F, Fellin F, Innocenzi M, Lipparini M, Lorentini S, Widesott L, et al. A pre-absorber optimization technique for pencil beam scanning proton therapy treatments. Phys Med. 2019;57:145\u201352.","journal-title":"Phys Med"},{"key":"1476_CR39","doi-asserted-by":"publisher","DOI":"10.1088\/2057-1976\/aa726a","volume":"3","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kerr MD, Guan F, Hartman J, Jiang B, Sahoo N, et al. Dose calculation for spot scanning proton therapy with the application of a range shifter. Biomed Phys Eng Express. 2017;3:035019.","journal-title":"Biomed Phys Eng Express"},{"key":"1476_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0b013e3181b6d4b7","volume":"15","author":"TE Merchant","year":"2009","unstructured":"Merchant TE. Proton beam therapy in pediatric oncology. Cancer J. 2009;15:8.","journal-title":"Cancer J"},{"key":"1476_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2176\/nmc.ra.2017-0003","volume":"57","author":"M Mizumoto","year":"2017","unstructured":"Mizumoto M, Oshiro Y, Yamamoto T, Kohzuki H, Sakurai H. Proton Beam Therapy for Pediatric Brain Tumor. Neurol Med Chir (Tokyo). 2017;57:343\u201355.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"1476_CR42","unstructured":"Stoyanov GS, Kitanova M, Dzhenkov DL, Ghenev P, Sapundzhiev N. Demographics of Head and Neck Cancer Patients: A Single Institution Experience. Cureus [Internet]. [cited 2019 Mar 23];9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5580971\/"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-020-1476-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T19:21:06Z","timestamp":1611861666000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-1476-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-1476-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient data used in this study is approved by Beaumont institutional review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Xuanfeng Ding, Xiaoqiang Li and Di Yan have a patent related to the Particle Arc Therapy (WO2017156419).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}